Healthcare & Pharmaceuticals

Enabling our pharmaceutical and healthcare clients to maximise opportunities and manage business challenges

KWM is one of the few international law firms with a specialised team dedicated specifically to pharmaceuticals, health care and life science matters with a focus on business in and out of Asia Pacific. KWM have represented numerous large international healthcare companies and government departments of health in Asia, Europe, Australia and other regions.

In London, our corporate and M&A team leverage our cross-border expertise to enable our pharmaceutical and healthcare clients to both maximise opportunities and manage business challenges.

We advise pharmaceutical companies (both originators and generics), biotechnology companies, research and development companies and medical devices manufacturers as well as private equity and venture capital firms on:

  • Corporate M&A - share and asset acquisitions and disposals
  • Private equity transactions and venture capital
  • Co-investments
  • Licensing and commercial exploitation particularly focussed on strategic collaborations, joint ventures and R&D arrangements
  • Public M&A/ Capital markets:
  • UK Code regulated takeovers
  • Schemes of arrangement
  • Block trades, PIPES and Shareholder activism
  • Initial Public Offerings
  • Dual and secondary listings
  • Secondary offerings including placings
  • Rights issues and open offers
  • Corporate Governance, Listing Rules, Disclosure and Transparency Rules, Continuing Obligations
  • Restructurings

In London, we also have broad experience across all aspects of major commercial disputes typically including multiple jurisdictions and also advise clients in relation to internal and regulator led investigations with a focus on corruption and sanctions investigations, self-reporting obligations, policies and procedures and potential criminal and civil liability.

Our recent experience includes advising

  • Luye PharmaGroup: Advised this Hong Kong listed group on its US$546 million acquisition of Seroquel and Seroquel XR pharmaceutical rights and assets from AstraZeneca. The transaction involved the sale and licence of the rights to the products in the UK, China and other 49 international markets.
  • Capital Dynamics: Advised the global private equity firm on co-investments into pharmaceutical packaging and distribution businesses in Europe and internationally.
  • Vaccitech: Advised UK-based Vaccitech, a spin-out company from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centres in the world, in its collaboration with China-based CanSino Biologics, to develop a new vaccine approach to prevent shingles (herpes zoster).  The documentation comprised master collaboration, licencing and technology transfer agreements.
  • Actavis: Advised on the disposal of a portfolio of woman’s health products and devices in various stages of development to Mithra Pharmaceuticals for an undisclosed sum. The transaction involved the drafting and negotiation of a complex conditional share sale and purchase agreement as well as an asset sale and other related principal documents.
  • KKR: Advised on its acquisition of a minority stake in $2.2 billion valued healthcare provider GenesisCare. The London team supported KWM Australia with the due diligence aspects of the transaction and finalization of the purchase agreement.
  • Xiuzheng Bio-medicine Research Institute: Advised on a licence and joint development agreement.
  • Ogawa Intelligent Health Technology: Advised on a share exchange transaction with a UK and German based medical devices business.
  • Agalimmune: Advised the selling shareholders on the disposal of the anti-cancer business Agalimmune Ltd, a private UK-based company with an innovative, anti-cancer immunotherapy platform, on the acquisition by BioLineRx Ltd, a clinical-stage biopharmaceutical company focused on oncology and immunology. The acquisition consideration consisted of an upfront payment in cash and the remainder in BioLineRx shares. Additional future payments may be made based on development and commercial milestones.
  • Teva: Advising Teva in parallel LCIA arbitrations arising from alleged non-supply under two supply agreements as part of a joint venture arrangement with Proctor & Gamble.  
  • Actavis: Advising in relation to claims following the US $40 billion acquisition by Teva of Allergan’s generic business. The claims included defending injunction proceedings and allegations relating to activities that took place in Dubai, Hong Kong, Switzerland and the U.K as regards royalty payments/calculations.
  • Chinese pharmaceutical Company: Acting in an English law governed HKIAC arbitration for a Chinese pharmaceutical company against a UK counterparty.  The dispute involved complicated claims for expectation and reliance loss arising from a licensing agreement for the development and sale of respiratory inhaler products.